Bio Techne Corp Net Income
| TECH Stock | USD 64.63 0.62 0.95% |
As of the 4th of February, Bio Techne shows the Downside Deviation of 1.76, mean deviation of 1.68, and Risk Adjusted Performance of 0.0366. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Bio Techne, as well as the relationship between them.
Bio Techne Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 8.4123 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 84.4 M | 89.2 M | |
| Net Income Applicable To Common Shares | 328.1 M | 344.5 M | |
| Net Income From Continuing Ops | 84.4 M | 155.3 M | |
| Net Income Per Share | 0.47 | 0.42 | |
| Net Income Per E B T | 0.67 | 0.58 |
Bio | Net Income | Build AI portfolio with Bio Stock |
The Net Income trend for Bio Techne Corp offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bio Techne is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Bio Techne's Net Income Growth Pattern
Below is the plot of the Net Income of Bio Techne Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bio Techne Corp financial statement analysis. It represents the amount of money remaining after all of Bio Techne Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bio Techne's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 73.4 M | 10 Years Trend |
|
Net Income |
| Timeline |
Bio Net Income Regression Statistics
| Arithmetic Mean | 128,657,965 | |
| Geometric Mean | 88,818,983 | |
| Coefficient Of Variation | 56.88 | |
| Mean Deviation | 53,157,079 | |
| Median | 110,948,000 | |
| Standard Deviation | 73,174,377 | |
| Sample Variance | 5354.5T | |
| Range | 284.9M | |
| R-Value | 0.34 | |
| Mean Square Error | 5063.1T | |
| R-Squared | 0.11 | |
| Significance | 0.19 | |
| Slope | 4,882,192 | |
| Total Sum of Squares | 85671.8T |
Bio Net Income History
Other Fundumenentals of Bio Techne Corp
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bio Techne Net Income component correlations
Bio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Techne is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Net Income. Since Bio Techne's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Techne's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Techne's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.143 | Dividend Share 0.32 | Earnings Share 0.49 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value - what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Bio Techne 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bio Techne's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bio Techne.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Bio Techne on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Bio Techne Corp or generate 0.0% return on investment in Bio Techne over 90 days. Bio Techne is related to or competes with Moderna, Exelixis, Biomarin Pharmaceutical, Madrigal Pharmaceuticals, Avidity Biosciences, Caris Life, and Jazz Pharmaceuticals. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instrum... More
Bio Techne Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bio Techne's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bio Techne Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.76 | |||
| Information Ratio | 0.0157 | |||
| Maximum Drawdown | 9.58 | |||
| Value At Risk | (2.90) | |||
| Potential Upside | 3.72 |
Bio Techne Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Techne's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bio Techne's standard deviation. In reality, there are many statistical measures that can use Bio Techne historical prices to predict the future Bio Techne's volatility.| Risk Adjusted Performance | 0.0366 | |||
| Jensen Alpha | 0.0157 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0187 | |||
| Treynor Ratio | 0.0542 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bio Techne's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bio Techne February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0366 | |||
| Market Risk Adjusted Performance | 0.0642 | |||
| Mean Deviation | 1.68 | |||
| Semi Deviation | 1.66 | |||
| Downside Deviation | 1.76 | |||
| Coefficient Of Variation | 2439.71 | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.39 | |||
| Information Ratio | 0.0157 | |||
| Jensen Alpha | 0.0157 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0187 | |||
| Treynor Ratio | 0.0542 | |||
| Maximum Drawdown | 9.58 | |||
| Value At Risk | (2.90) | |||
| Potential Upside | 3.72 | |||
| Downside Variance | 3.09 | |||
| Semi Variance | 2.76 | |||
| Expected Short fall | (1.99) | |||
| Skewness | 0.539 | |||
| Kurtosis | (0.26) |
Bio Techne Corp Backtested Returns
Bio Techne appears to be very steady, given 3 months investment horizon. Bio Techne Corp secures Sharpe Ratio (or Efficiency) of 0.0953, which signifies that the company had a 0.0953 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Bio Techne Corp, which you can use to evaluate the volatility of the firm. Please makes use of Bio Techne's Mean Deviation of 1.68, downside deviation of 1.76, and Risk Adjusted Performance of 0.0366 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bio Techne holds a performance score of 7. The firm shows a Beta (market volatility) of 1.4, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Techne will likely underperform. Please check Bio Techne's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Bio Techne's price patterns will revert.
Auto-correlation | 0.58 |
Modest predictability
Bio Techne Corp has modest predictability. Overlapping area represents the amount of predictability between Bio Techne time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bio Techne Corp price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Bio Techne price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 15.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bio Techne Corp reported net income of 73.4 M. This is 78.49% lower than that of the Life Sciences Tools & Services sector and 4.79% higher than that of the Health Care industry. The net income for all United States stocks is 87.14% higher than that of the company.
Bio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in net income category among its peers.
Bio Techne ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Techne's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Techne's managers, analysts, and investors.Environmental | Governance | Social |
Bio Techne Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Techne that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bio Techne's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Techne's value.| Shares | Mairs & Power Inc | 2025-06-30 | 2.7 M | Champlain Investment Partners, Llc | 2025-06-30 | 2.7 M | Mackenzie Investments | 2025-06-30 | 2.6 M | Neuberger Berman Group Llc | 2025-06-30 | 2.5 M | Citadel Advisors Llc | 2025-06-30 | 2.5 M | Sumitomo Mitsui Trust Group Inc | 2025-06-30 | 2.3 M | Rgm Capital Llc | 2025-06-30 | 2.2 M | Bank Of New York Mellon Corp | 2025-06-30 | 1.9 M | Norges Bank | 2025-06-30 | 1.9 M | Vanguard Group Inc | 2025-06-30 | 18.4 M | Blackrock Inc | 2025-06-30 | 12.2 M |
Bio Fundamentals
| Return On Equity | 0.038 | ||||
| Return On Asset | 0.0625 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 10.22 B | ||||
| Shares Outstanding | 155.81 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 99.72 % | ||||
| Number Of Shares Shorted | 10.36 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 5.08 X | ||||
| Price To Sales | 8.36 X | ||||
| Revenue | 1.22 B | ||||
| Gross Profit | 813.2 M | ||||
| EBITDA | 216.88 M | ||||
| Net Income | 73.4 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 444.06 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 12.62 X | ||||
| Cash Flow From Operations | 287.56 M | ||||
| Short Ratio | 5.64 X | ||||
| Earnings Per Share | 0.49 X | ||||
| Price To Earnings To Growth | 0.83 X | ||||
| Target Price | 70.0 | ||||
| Number Of Employees | 3.1 K | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 10.17 B | ||||
| Total Asset | 2.56 B | ||||
| Retained Earnings | 1.07 B | ||||
| Working Capital | 432.45 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
| Annual Yield | 0 % | ||||
| Five Year Return | 0.56 % | ||||
| Net Asset | 2.56 B | ||||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is there potential for Life Sciences Tools & Services market expansion? Will Bio introduce new products? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.143 | Dividend Share 0.32 | Earnings Share 0.49 | Revenue Per Share | Quarterly Revenue Growth (0.01) |
Understanding Bio Techne Corp requires distinguishing between market price and book value, where the latter reflects Bio's accounting equity. The concept of intrinsic value - what Bio Techne's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bio Techne's price substantially above or below its fundamental value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Bio Techne's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.